NO20071322L - Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav - Google Patents

Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav

Info

Publication number
NO20071322L
NO20071322L NO20071322A NO20071322A NO20071322L NO 20071322 L NO20071322 L NO 20071322L NO 20071322 A NO20071322 A NO 20071322A NO 20071322 A NO20071322 A NO 20071322A NO 20071322 L NO20071322 L NO 20071322L
Authority
NO
Norway
Prior art keywords
growth hormone
human growth
preparation
polyethylene glycol
branched polyethylene
Prior art date
Application number
NO20071322A
Other languages
English (en)
Inventor
Rory F Finn
Ned R Siegel
Original Assignee
Pharmacia & Upjohn Co Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=35708806&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20071322(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Pharmacia & Upjohn Co Llc filed Critical Pharmacia & Upjohn Co Llc
Publication of NO20071322L publication Critical patent/NO20071322L/no

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/02—Drugs for disorders of the endocrine system of the hypothalamic hormones, e.g. TRH, GnRH, CRH, GRH, somatostatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Endocrinology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Reproductive Health (AREA)
  • Rheumatology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Urology & Nephrology (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • Pain & Pain Management (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Vascular Medicine (AREA)
  • Pregnancy & Childbirth (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Cardiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Det beskrives en PEGylering av menneskelig veksthormon (hGH) ved bruk av et glycerolforgrenet PEG. Det beskrives videre prosesser for PEGylering av hGH. I tillegg beskriver oppfinnelsen farmasøytiske preparater omfattende PEGylert hGH. En ytterligere utførelsesform er bruken av PEGylert hGH for behandling av vekst- og utviklingsforstyrrelser.
NO20071322A 2004-08-31 2007-03-09 Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav NO20071322L (no)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US60594504P 2004-08-31 2004-08-31
PCT/IB2005/002939 WO2006024953A2 (en) 2004-08-31 2005-08-25 Glycerol branched polyethylene glycol human growth hormone conjugates, process for their preparation, and methods of use thereof

Publications (1)

Publication Number Publication Date
NO20071322L true NO20071322L (no) 2007-05-29

Family

ID=35708806

Family Applications (1)

Application Number Title Priority Date Filing Date
NO20071322A NO20071322L (no) 2004-08-31 2007-03-09 Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav

Country Status (24)

Country Link
EP (1) EP1789092A2 (no)
JP (1) JP2008511610A (no)
KR (1) KR20070042567A (no)
CN (1) CN101010105A (no)
AP (1) AP2007003919A0 (no)
AR (1) AR050851A1 (no)
AU (1) AU2005278903A1 (no)
BR (1) BRPI0515118A (no)
CA (1) CA2577999A1 (no)
CR (1) CR8942A (no)
EA (1) EA200700380A1 (no)
EC (1) ECSP077281A (no)
GT (1) GT200500235A (no)
IL (1) IL181085A0 (no)
MA (1) MA28908B1 (no)
MX (1) MX2007002441A (no)
NL (1) NL1029828C2 (no)
NO (1) NO20071322L (no)
PE (1) PE20060654A1 (no)
TN (1) TNSN07078A1 (no)
TW (1) TW200621291A (no)
UY (1) UY29088A1 (no)
WO (1) WO2006024953A2 (no)
ZA (1) ZA200701802B (no)

Families Citing this family (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE375363T1 (de) 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
US7495087B2 (en) 1997-07-14 2009-02-24 Bolder Biotechnology, Inc. Cysteine muteins in the C-D loop of human interleukin-11
BR122013003013B8 (pt) 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
US7855279B2 (en) 2005-09-27 2010-12-21 Amunix Operating, Inc. Unstructured recombinant polymers and uses thereof
EP1834963A1 (en) * 2006-03-13 2007-09-19 Siegfried Ltd. Di-polymer protein conjugates and processes for their preparation
MX2008014358A (es) * 2006-05-12 2008-11-24 Dong A Pharm Co Ltd Conjugado de polietilenglicol-interferon alfa.
JP2008069073A (ja) * 2006-09-12 2008-03-27 Yokohama Tlo Co Ltd ラクトフェリン複合体及びその製造方法
KR101079993B1 (ko) 2006-11-17 2011-11-04 동아제약주식회사 폴리에틸렌글리콜 과립구 콜로니 자극인자 접합체
CL2008002399A1 (es) 2007-08-16 2009-01-02 Pharmaessentia Corp Conjugado sustancialmente puro que posee una porcion polimerica, una porcion proteica (interferon alfa 2b) y un ligante alifatico de 1 a 10 atomos de carbono, util en el tratamiento de las hepatitis b o c.
UA101670C2 (ru) * 2008-07-23 2013-04-25 Ханми Сайенс Ко., Лтд. Полипептидный комплекс, содержащий непептидильный полимер, который имеет три функциональных конца
MY156568A (en) 2008-07-31 2016-03-15 Pharmaessentia Corp Peptide-polymer conjugates
US8535655B2 (en) 2008-10-10 2013-09-17 Polyactiva Pty Ltd. Biodegradable polymer—bioactive moiety conjugates
MY155629A (en) * 2008-10-10 2015-11-13 Polyactiva Pty Ltd Biodegradable polymer-bioactive moiety conjugates
SI2340271T1 (sl) * 2008-10-10 2019-08-30 Polyactiva Pty Ltd. Konjugati polimer-bioaktivnega sredstva
US8680050B2 (en) 2009-02-03 2014-03-25 Amunix Operating Inc. Growth hormone polypeptides fused to extended recombinant polypeptides and methods of making and using same
CA2748314C (en) 2009-02-03 2018-10-02 Amunix Operating Inc. Extended recombinant polypeptides and compositions comprising same
US8703717B2 (en) 2009-02-03 2014-04-22 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
US9849188B2 (en) 2009-06-08 2017-12-26 Amunix Operating Inc. Growth hormone polypeptides and methods of making and using same
JP6086528B2 (ja) 2009-08-06 2017-03-01 ノヴォ・ノルディスク・ヘルス・ケア・アーゲー 長期のインビボ有効性を有する成長ホルモン
CN101831067A (zh) * 2010-05-31 2010-09-15 王二新 聚乙二醇脂类缀合物及其在制备药物中的应用
EP2446898A1 (en) 2010-09-30 2012-05-02 Laboratorios Del. Dr. Esteve, S.A. Use of growth hormone to enhance the immune response in immunosuppressed patients
CN102367290B (zh) * 2011-04-26 2013-05-08 厦门赛诺邦格生物科技有限公司 链官能化的多级支化聚乙二醇及其合成方法
CN117462693A (zh) * 2012-02-27 2024-01-30 阿穆尼克斯运营公司 Xten缀合组合物和制造其的方法
DK2947111T3 (en) * 2013-01-17 2018-05-07 Xiamen Sinopeg Biotech Co Ltd MONOFUNCTIONAL BRANCHED POLYETHYLENE LYCOL AND BIORELATED SUBSTANCE MODIFIED BY SAME
CN104877127B (zh) 2015-06-23 2017-11-10 厦门赛诺邦格生物科技股份有限公司 一种八臂聚乙二醇衍生物、制备方法及其修饰的生物相关物质
US11559567B2 (en) 2014-11-06 2023-01-24 Pharmaessentia Corporation Dosage regimen for pegylated interferon
HRP20220041T1 (hr) 2017-12-29 2022-04-15 F. Hoffmann - La Roche Ag Postupak za dobivanje pegiliranog proteinskog pripravka
CN111741770A (zh) * 2017-12-29 2020-10-02 豪夫迈·罗氏有限公司 用于提供聚乙二醇化蛋白质组合物的方法
WO2019129878A1 (en) * 2017-12-29 2019-07-04 F. Hoffmann-La Roche Ag Process for providing pegylated protein composition

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993000109A1 (en) * 1991-06-28 1993-01-07 Genentech, Inc. Method of stimulating immune response using growth hormone
JP3092531B2 (ja) * 1996-11-05 2000-09-25 日本油脂株式会社 コハク酸イミジル基置換ポリオキシアルキレン誘導体の製造方法
ATE375363T1 (de) * 1997-07-14 2007-10-15 Bolder Biotechnology Inc Derivate des wachstumshormons und verwandte proteine
JP3921781B2 (ja) * 1998-02-12 2007-05-30 日本油脂株式会社 カルボキシル基含有ポリオキシアルキレン化合物
BR122013003013B8 (pt) * 1999-01-14 2021-07-06 Bolder Biotechnology Inc proteína isolada monopeguilada do hormônio do crescimento e método para sua obtenção
AP2004003050A0 (en) * 2001-11-20 2004-06-30 Pharmacia Corp Chemically modified human growth hormone conjugates
NZ540490A (en) * 2002-09-09 2007-10-26 Nektar Therapeutics Al Corp Water-soluble polymer alkanal conjugates with human growth hormone
JP4412461B2 (ja) * 2002-11-20 2010-02-10 日油株式会社 修飾された生体関連物質、その製造方法および中間体
CA2509248A1 (en) * 2002-12-31 2004-07-22 Nektar Therapeutics Al, Corporation Polymeric reagents comprising a ketone or a related functional group
TR201907313T4 (tr) * 2003-05-23 2019-06-21 Nektar Therapeutics İki PEG zinciri içeren PEG türevleri.

Also Published As

Publication number Publication date
CA2577999A1 (en) 2006-03-09
WO2006024953A3 (en) 2007-01-18
CR8942A (es) 2007-08-16
JP2008511610A (ja) 2008-04-17
AR050851A1 (es) 2006-11-29
MX2007002441A (es) 2007-05-04
CN101010105A (zh) 2007-08-01
ECSP077281A (es) 2007-03-29
GT200500235A (es) 2006-03-21
NL1029828C2 (nl) 2006-10-20
PE20060654A1 (es) 2006-08-12
ZA200701802B (en) 2008-08-27
TW200621291A (en) 2006-07-01
TNSN07078A1 (fr) 2008-06-02
AU2005278903A1 (en) 2006-03-09
AP2007003919A0 (en) 2007-02-28
EP1789092A2 (en) 2007-05-30
WO2006024953A2 (en) 2006-03-09
BRPI0515118A (pt) 2008-07-01
EA200700380A1 (ru) 2007-10-26
UY29088A1 (es) 2006-03-31
KR20070042567A (ko) 2007-04-23
NL1029828A1 (nl) 2006-03-01
MA28908B1 (fr) 2007-10-01
IL181085A0 (en) 2007-07-04

Similar Documents

Publication Publication Date Title
NO20071322L (no) Humane veksthormonkonjugater av glyserolforgrenet polyetylenglycol, fremgangsmate for dens fremstilling og fremgangsmate for anvendelse derav
BRPI0418745A (pt) anticorpo linhagem de células, composição farmacêutica, e, método de tratamento de cáncer em um paciente
DK1079806T3 (da) Præparater til påföringen af antiinflammatoriske, især antiseptiske midler og/eller midler, der fremmer helingen af sår, til de övre luftveje og/eller öret
NO20063926L (no) N-terminale monopegylerte humane veksthormonkonjugater, fremgangsmater for fremstilling og anvendelse av disse
EA200700431A1 (ru) Конъюгаты химически модифицированного гормона роста человека
RU2008145084A (ru) Аналоги фактора ix, имеющие пролонгированное время полужизни in vivo
NO20060924L (no) Sammensetning av en VEGF- antagonist og en anti-proliferativ agens
WO2006058539A3 (en) Growth hormone secretagogue receptor 1a ligands
CY1112257T1 (el) Μεθοδοι αγωγης των φλεγμονωδων παθησεων χρησιμοποιωντας ειδικους παραγοντες δεσμευσης της ανθρωπινης αγγειοποιητινης-2
DE60323090D1 (de) 1h-imidazoä4,5-cüchinolinderivate zur behandlung von protein kinase-abhängigen krankheiten
UA81629C2 (ru) Применение композиции и способ лечения инфекционных заболеваний крупного рогатого скота и свиней
WO2006004959A3 (en) Pegylated interferon alpha-1b
WO2008082507A3 (en) Pharmaceutical compositions and method for treating inflammation in cattle and other animals
DK1223990T3 (da) Formuleringer af hyaluronsyre til tilförsel af osteogene proteiner
NO20045354L (no) Fremgangsmater for behandling av angiogenese, turmorvekst og metastaser
ATE470443T1 (de) Indol-1-yl-essigsäurederivate
DK2229440T3 (da) Rekombinante elastase-proteiner og fremgangsmåder til fremstilling og anvendelse deraf
DE50211137D1 (de) Seitenkettenhalogenierte aminodicarbonsaurederivate als arzneimittel zur behandlung von herz-kreislauf-erkrankungen
DE60142913D1 (de) Arzneilösungen enthaltend modafinilverbindungen
EP1499190A4 (en) METHODS OF TREATING LIVER DISEASES AND LIVER LESIONS USING GROWTH HORMONE AND FOXM1B PROTEIN
WO2003093419A3 (en) Preventing secondary lymphedema with vegf-d dna
NO20024673D0 (no) Farmasöytisk sammensetning med kontrollert frigivning for oral anvendelse inneholdende midodrin og/eller desglymidodrin
WO2007050121A3 (en) Site specific pegylated hemoglobin, method of preparing same, and uses thereof
DK1596879T3 (da) Anvendelse af kahalalidforbindelser til fremstilling af et medikament til behandling af psoriasis
EA200500175A1 (ru) Соль морфин-6-глюкуронида

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application